Brief: Cynata Therapeutics Gets EU Regulatory & Ethics Approval For Phase 2 Trial In Graft Versus Host Disease
20/03/2024 01:12
March 20 (Reuters) - Cynata Therapeutics Ltd CYP.AX :
* EU REGULATORY & ETHICS APPROVAL FOR PHASE 2 TRIAL OF
CYP-001 IN
GRAFT VERSUS HOST DISEASE
Further company coverage: CYP.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cynata Therapeutics
See all newsBrief: Cynata Therapeutics Says Firm Commitments Received To Raise Further A$550,000 Via Placement
Brief: Cynata Therapeutics Enters Consultancy Agreement With LIR Bio Advisory
Brief: Cynata Therapeutics Establishes Share Sale Facility For Unmarketable Parcel Holders
Brief: Cynata Therapeutics Terminates Of At-The-Market Subscription Deed
Brief: Cynata Therapeutics Posts FY2026 Loss From Ordinary Activities After Tax A$9.1 Million